| OMC |
Report |
Operating diluted EPS |
IN-LINE |
pred ~$2.60 vs. cons $2.61 |
MEDIUM |
| OMC |
Report |
Core organic revenue growth |
MISS |
pred ~3.50% vs. cons 3.63% |
MEDIUM |
| OMC |
Report |
Operating EBITDA |
IN-LINE |
pred ~$1.205B vs. cons $1.212B |
MEDIUM |
| OMC |
Guide |
Core organic growth (FY26) |
BETTER |
guide ~4.0% vs. cons 3.73% |
MEDIUM |
| OMC |
Guide |
Cost reductions (FY26) |
UNCHANGED |
guide ~$900M vs. cons UNVERIFIED |
LOW |
| OMC |
Return |
Day-1 residual (stock − beta × S&P 500) |
-1.5% |
— |
LOW |
| OMC |
Return |
5-day cumulative residual |
-3.0% (FOLLOW-THROUGH) |
FOLLOW-THROUGH — implied H2 organic-growth burden drives estimate risk |
LOW |